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Outcome of atrial fibrillation after mitral valve
repair
To the Editor:
The article by Obadia and associates1 in the August
1997 issue of this Journal evaluates some of the factors
that influence the return to sinus rhythm (SR) from
preoperative atrial fibrillation (AF) after mitral valve
repair. I shall only be referring to those patients whom the
authors have called the permanent fibrillation group
(about 70% of their patients with AF). Duration of AF
was the most important factor identified, being more
predictive than left atrial diameter. Although this is widely
acknowledged to be the case, another prognostic factor
that helps to identify patients whose rhythm is likely to
revert to SR, and possibly continue in SR in the late
postoperative period, is the outcome of primary cardio-
version intraoperatively.
I would like to share our experience with patients in AF
undergoing mitral valve replacement (MVR), which we
published some years back2 and believe is equally perti-
nent in mitral valve repair.
In all patients with AF who were undergoing MVR, we
tried intraoperative direct-current cardioversion (primary
cardioversion) soon after separation from cardiopulmo-
nary bypass. Synchronized shocks of 10 to 50 joules were
delivered to the heart, and attempts were made to capture
the SR, if present, on biatrial pacing. Pacing was contin-
ued for 48 to 72 hours after the operation if this primary
cardioversion was successful. Logically, such patients
(group A) would be in a superior hemodynamic state
in the critical postoperative period in the intensive care
unit than those whose rhythm did not convert to SR
(group B). All discharged patients of group B, and those
of group A whose rhythm reverted to AF after only a few
days of SR, were called back for a secondary cardioversion
after varying intervals in the postoperative follow-up. We
studied 75 such patients prospectively over a 4-year pe-
riod.
We observed that the results of secondary cardioversion
were much better in group A patients (80.9% immediate
conversion to SR) than in group B (36.4% conversion to
SR). Also, at the end of 1 year, 55.5% of group A patients
and only 19.3% in group B were still in SR. The most
likely candidate for a successful cardioversion in our study
was a patient with a duration of AF less than 2 years and
in whom it was possible to convert to SR at the time of the
operation. On the basis of these conclusions, we recom-
mended that all patients in AF undergoing MVR should
have an electric cardioversion during the operation. If
successful, SR should be maintained by atrial pacing for
48 to 72 hours for a smoother immediate postoperative
recovery. When discharged patients in AF are called in for
a secondary cardioversion, success is more likely if the
response to primary cardioversion was positive, even if the
SR did not last long.
Anoop K. Ganjoo, MCh, DNB, FIACS
Specialist, Cardiothoracic Surgery
St. Stephen’s Hospital
Tis Hazari
Delhi 110054 India
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Single or bilateral lung transplantation for
chronic obstructive pulmonary disease
To the Editor:
We read with interest the article by Bavaria and col-
leagues1 concerning bilateral (BLT) versus single (SLT)
lung transplantation for chronic obstructive pulmonary
disease (COPD) and would like to make the following
comments:
The primary indication for transplantation in COPD is
to relieve the patient’s symptoms, not to improve longev-
ity. It is therefore difficult to justify the use of a pair of
lungs in patients with COPD when there is an ever-
increasing and obligatory need for BLT in patients with
cystic fibrosis.
We believe it is difficult to draw any comparison,
because the groups differed demographically.
The mean ages of the two groups differed substantially,
the BLT recipients being significantly younger (48.8 vs
55.3 years, p , 0.001). More than half of the BLT
recipients were men, compared with less than a third of
the SLT recipients (58.6% vs 27.7%: p 5 0.007). There is
sufficient data to show that patients less than 50 years of
age have a significantly improved life expectancy and that
being male gives one a better chance of survival than
being female.2 Finally, we were surprised that the authors
could “favorably compare” their 28.3% 1-year mortality
for the SLT recipients to the Washington University figure
of 10.3%.3 Indeed, survival figures from the Heart and
Lung Transplant Registry indicate 1-year mortality for
SLT and BLT to be 19.81% and 17.96%, respectively (p .
0.05).2
Although we entirely agree that BLT would result in
better pulmonary function, quality of life, and life expect-
ancy, it is hard to justify the practice of BLT in patients
with COPD, and confusion may occur when such figures
are quoted without comparing two demographically sim-
ilar groups.
Catherine D. Sudarshan, FRCS
Stephen C. Clark, FRCS
John H. Dark, FRCS
Department of Cardiopulmonary Transplantation,
Freeman Hospital
Newcastle upon Tyne NE7 7DN, United Kingdom
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